Transcatheter Aortic Valve Implantation for Patients with Severe Symptomatic Aortic Stenosis


 The cost-effectiveness of transcatheter aortic valve implantation (TAVI) compared to surgical replacement was examined in patients with severe symptomatic stenosis at high, intermediate, and low risk, the findings were mixed. When replacement, some studies suggest that TAVI is cost-effective (less costly and/or more effective) not cost-effective.
 Factors such as type system used, cost treatment-associated expenses (such post-operative follow-up costs hospitalization costs), characteristics selected for treatment likely impact stenosis.